The implementation of ICH E14/S7B advancements, including C-QTc modeling and alternative approaches, has significantly reduced the need for resource-intensive Thorough QT studies and decreased clinical trial sample sizes.
No takes yet. Share an insight, caveat, or question.
Guideline-driven C-QTc adoption cuts TQT studies and sample sizes; leaves open optimal cardiac safety integration in drug development.
Ji et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: